Genelux Corporation Common Stock
GNLXGenelux Corporation is a biotechnology company specializing in the development of targeted cancer therapies. It focuses on leveraging proprietary tumor-targeting technologies to develop innovative treatments aimed at improving outcomes for cancer patients.
Company News
Genelux Corporation announced that its President, CEO, and Chairman Thomas Zindrick, along with CFO Matt Pulisic and Chief Medical Officer Dr. Jason Litten, will participate in a virtual fireside chat on January 19, 2026. The company is a late clinical-stage biopharmaceutical firm developing oncolytic immunotherapies, with its lead candidate Olvi...
Genelux Corporation announced the appointment of Jason Litten, M.D., as Chief Medical Officer effective January 2, 2026. Dr. Litten brings over 20 years of biopharmaceutical experience and will oversee clinical development and medical strategy for Olvi-Vec, the company's oncolytic immunotherapy candidate currently in Phase 2/3 trials for ovarian ...
Genelux Corporation, a late clinical-stage immuno-oncology company, announced that its President, Chairman and CEO will discuss the company's clinical-stage programs, recent announcements, and upcoming milestones at the H.C. Wainwright Global Healthcare Conference.
Genelux Corporation, a late clinical-stage immuno-oncology company, announced that its President, CEO and Chairman will discuss the company's clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG's Virtual Biotechnology Conference 2024.
Genelux (NASDAQ:GNLX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish B...
